Interaksi Dapagliflozin dan Repaglinid

Dapagliflozin dan Repaglinid: kedua label peresepan menguraikan interaksi yang biasanya memerlukan pemantauan, perubahan dosis, atau pemberian jarak antardosis.

Moderat

Biasanya dapat dikelola dengan pemantauan atau perubahan dosis. Beri tahu apoteker Anda bahwa Anda menggunakan keduanya.

Apa kata label FDA

Dari label Dapagliflozin · berlaku sejak 2026-06-03

Moderat

• Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with DAPAGLIFLOZIN TABLETS.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues Insulin and insulin secretagogues (e.g., sulfonylureas) are known to cause hypoglycemia.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

DAPAGLIFLOZIN TABLETS may increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue [see Adverse Reactions (6.1) ] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with DAPAGLIFLOZIN TABLETS [see Drug Interactions (7) ] .

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Table 4: Clinically Relevant Interactions with DAPAGLIFLOZIN TABLETS Insulin or Insulin Secretagogues Clinical Impact The risk of hypoglycemia may be increased when DAPAGLIFLOZIN TABLETS are used concomitantly with insulin or insulin secretagogues (e.g., sulfonylurea) [see Warnings and Precautions (5.4) ] .

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Dari label Repaglinid (Repaglinide) · berlaku sejak 2025-05-02

Moderat

Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content), changes in level of physical activity, changes to co-administered medication [see Drug Interactions (7) ] , and concomitant use with other antidiabetic agents.

Peringatan dan perhatianberdasarkan golongan obatLihat label di DailyMed
Moderat

Drugs That May Decrease the Blood Glucose Lowering Effect of Repaglinide Tablets Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co-administered.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Moderat

CYP2C8 and CYP3A4 Inducers and Drugs That May Decrease the Blood Glucose Lowering Effect of repaglinide tablets : Co-administration may require repaglinide tablets dose increases and increased frequency of glucose monitoring ( 7 )

Interaksi obatberdasarkan golongan obatLihat label di DailyMed
Minor

Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.

Interaksi obatberdasarkan golongan obatLihat label di DailyMed

Menggunakan lebih dari dua obat ini? Interaksi saling bertumpuk. Periksa seluruh daftar Anda sekaligus; daftar itu tetap berada di peramban Anda.

Buka di pemeriksa

Bukan nasihat medis. Interaction Checker mengutip teks label FDA dan lembar fakta NIH. Penting atau tidaknya suatu interaksi bagi Anda bergantung pada dosis, waktu penggunaan, fungsi ginjal dan hati, serta kondisi lain. Pastikan dengan apoteker atau dokter yang meresepkan.